NDAORALTABLETPriority Review
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
CYTOMEL (liothyronine sodium) by Pfizer is synthesis. First approved in 1956.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYTOMEL is a synthetic liothyronine sodium (T3) thyroid hormone replacement used to treat hypothyroidism and myxedema coma. It works by binding to thyroid receptor proteins in cell nuclei, activating gene transcription and increasing metabolic rate. T3 is the more physiologically active form of thyroid hormone, providing faster onset than T4-based therapies.
$0.002BPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $2M annually, this franchise represents a mature, stable maintenance product with limited growth opportunities and a contracted commercial footprint.
Mechanism of Action
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYTOMEL offers limited upside for career growth but provides stable, deep expertise in endocrinology and mature product management. Professionals should expect focus on cost management, generic defense, and maintaining market access rather than revenue growth or innovation leadership.
Brand Manager
Worked on CYTOMEL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.